Q3 Earnings Estimate for RNA Issued By HC Wainwright

Key Points

• HC Wainwright projects a Q3 2026 loss of $2.31 per share for Avidity Biosciences and maintains a Buy rating with a $25 price target. The firm also estimates a $7.89 per-share loss for full-year 2026.
• Avidity’s latest quarterly results beat expectations, with an adjusted loss of $0.97 per share versus the $1.05 consensus estimate and revenue of $19.64 million, well above the $2 million forecast.
• Despite several positive analyst ratings, the stock carries a consensus Hold rating and opened at $12.34, near its 52-week low of $11.13; its 200-day moving average is $24.83.

Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) - Investment analysts at HC Wainwright issued their Q3 2026 EPS estimates for Avidity Biosciences in a research note issued on Thursday, August 6th. HC Wainwright analyst M. Kapoor expects that the biotechnology company will post earnings of ($2.31) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $25.00 target price on the stock. The consensus estimate for Avidity Biosciences' current full-year earnings is ($5.74) per share. HC Wainwright also issued estimates for Avidity Biosciences' Q4 2026 earnings at ($2.42) EPS, FY2026 earnings at ($7.89) EPS, Q1 2027 earnings at ($2.63) EPS, Q2 2027 earnings at ($2.67) EPS, Q3 2027 earnings at ($2.74) EPS, Q4 2027 earnings at ($2.24) EPS and FY2027 earnings at ($10.29) EPS.

Avidity Biosciences (NASDAQ:RNA - Get Free Report) last posted its earnings results on Thursday, May 14th. The biotechnology company reported ($0.97) EPS for the quarter, topping analysts' consensus estimates of ($1.05) by $0.08. The company had revenue of $19.64 million during the quarter, compared to the consensus estimate of $2.00 million.

Several other brokerages have also recently issued reports on RNA. Zacks Research raised Avidity Biosciences to a "hold" rating in a research report on Friday, June 19th. Weiss Ratings upgraded shares of Avidity Biosciences from a "sell (e-)" rating to a "sell (e)" rating in a research note on Monday, August 3rd. Cantor Fitzgerald initiated coverage on shares of Avidity Biosciences in a report on Thursday, June 18th. They issued an "overweight" rating and a $25.00 price objective on the stock. Wall Street Zen upgraded shares of Avidity Biosciences from a "sell" rating to a "hold" rating in a research report on Saturday, May 30th. Finally, Leerink Partners started coverage on shares of Avidity Biosciences in a research report on Friday, May 15th. They issued an "outperform" rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $63.85.

Avidity Biosciences Stock Performance

Avidity Biosciences stock opened at $12.34 on Monday. Avidity Biosciences has a one year low of $11.13 and a one year high of $16.77. The stock has a fifty day moving average of $12.36 and a 200 day moving average of $24.83. The stock has a market cap of $211.14 million and a PE ratio of -12.72.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. EFG International AG purchased a new stake in shares of Avidity Biosciences in the fourth quarter worth $33,000. Los Angeles Capital Management LLC bought a new position in shares of Avidity Biosciences in the fourth quarter worth about $34,000. Smartleaf Asset Management LLC raised its position in shares of Avidity Biosciences by 426.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 490 shares of the biotechnology company's stock valued at $35,000 after buying an additional 397 shares during the last quarter. Osaic Holdings Inc. increased its holdings in Avidity Biosciences by 1,659.1% in the 2nd quarter. Osaic Holdings Inc. now owns 1,636 shares of the biotechnology company's stock valued at $48,000 after acquiring an additional 1,543 shares during the last quarter. Finally, Comerica Bank lifted its stake in Avidity Biosciences by 75.9% in the 3rd quarter. Comerica Bank now owns 1,335 shares of the biotechnology company's stock worth $58,000 after purchasing an additional 576 shares in the last quarter.

About Avidity Biosciences

Avidity Biosciences is a clinical-stage biotechnology company dedicated to developing antibody-oligonucleotide conjugate (AOC) therapies designed to address serious neuromuscular and cardiac diseases. The company's proprietary AOC platform combines the targeting specificity of monoclonal antibodies with the gene-modulating power of oligonucleotides to deliver therapeutic agents directly into muscle cells. Headquartered in La Jolla, California, Avidity seeks to overcome traditional delivery challenges associated with RNA-based medicines by leveraging receptor-mediated uptake mechanisms.

The company's lead product candidate, AOC 1001, is in clinical development for myotonic dystrophy type 1 (DM1) and represents the first application of the AOC platform in a human study.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source